BTG gets positive approval for ZYTIGA

ZYTIGA, the prostate cancer treatment drug developed by specialist healthcare company BTG, has been approved by the European Medicines Agency (EMA), the firm announced on Tuesday morning.

ZYTIGA, the prostate cancer treatment drug developed by specialist healthcare company BTG, has been approved by the European Medicines Agency (EMA), the firm announced on Tuesday morning.

BTG, which develops and commercialises pharmaceutical products, highlighted the announcement by pharmaceuticals group Janssen-Cilag International that the Committee for Medial Products for Human Use (CHMP) of the EMA has "granted a positive opinion recommending approval" of ZYTIGA.

ZYTIGA, otherwise known as abiraterone acetate, is the oral, once-daily medication for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

"If endorsed by the European Commission, the recommendation would expand the indication for ZYTIGA, which is currently approved for use in combination withprednisone/prednisolone to treat men with mCRPC whose disease has progressed on or after a docetaxel-based chemotherapy regimen."

Janssen expects to receive the regulatory decision from the European Commission in early 2013.

"This positive opinion brings us a step closer to being able to offer ZYTIGA to advanced cancer patients earlier in the course of their disease and fills a previously unmet medical need," said Jane Griffiths, the Chairman of Janssen's Middle-East and African division.

"If approved, the expanded indication will provide a welcome new option for patients with castration-resistant prostate cancer. It could not only give men a chance of extended survival, but may also delay the need for chemotherapy and help to improve their quality of life."

Recommended

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
6 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023
The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
2 Feb 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023

Most Popular

Share tips of the week – 3 February 2023
Investments

Share tips of the week – 3 February 2023

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages
3 Feb 2023
The best one-year fixed savings accounts - February 2023
Savings

The best one-year fixed savings accounts - February 2023

Earn almost 5% on one-year fixed savings accounts.
6 Feb 2023
Will energy prices go down in 2023?
Personal finance

Will energy prices go down in 2023?

Wholesale gas prices are on a downward trajectory, but does this mean lower energy bills later this year?
6 Feb 2023